Log in

Relevant bibliographies by topics / Hypotensive agents – Pharmacokinetics / Journal articles

To see the other types of publications on this topic, follow the link: Hypotensive agents – Pharmacokinetics.

Journal articles on the topic 'Hypotensive agents – Pharmacokinetics'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 24 journal articles for your research on the topic 'Hypotensive agents – Pharmacokinetics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Misra, Debashish, Arthur Frankel, Philip Hall, et al. "The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML)." Blood 104, no. 11 (2004): 4513. http://dx.doi.org/10.1182/blood.v104.11.4513.4513.

Full text

Abstract:

Abstract Background: Although complete remission rates for AML are near 70% with combination induction and consolidation chemotherapy, most patients will relapse and die from the disease or treatment complications. New agents with unique mechanisms are needed. One such class of therapeutics are fusion proteins consisting of protein synthesis inactivating peptide toxins fused to tumor cell selective ligands. DT388-IL3 is one such fusion protein. Rationale: In preclinical studies, DT388-IL3 was cytotoxic to the IL3 receptor expressing leukemia cell lines but not toxic to IL3 receptor negative ce

APA, Harvard, Vancouver, ISO, and other styles

2

Baidas, Said M., Eric P. Winer, Gini F. Fleming, et al. "Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer." Journal of Clinical Oncology 18, no. 14 (2000): 2710–17. http://dx.doi.org/10.1200/jco.2000.18.14.2710.

Full text

Abstract:

PURPOSE: To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer. PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 200 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pretreated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated. RESULTS: No patient had a true partial or compl

APA, Harvard, Vancouver, ISO, and other styles

3

Clark, Justin A., and David S. Burgess. "Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance." Therapeutic Advances in Infectious Disease 7 (January 2020): 204993612095260. http://dx.doi.org/10.1177/2049936120952604.

Full text

Abstract:

Objective: To review the mechanism of action, mechanisms of resistance, in vitro activity, pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside. Data sources: A PubMed search was performed from January 2006 to August 2019 using the following search terms: plazomicin and ACHN-490. Another search was conducted on clinicaltrials.gov for published clinical data. References from selected studies were also used to find additional literature. Study selection and data extraction: All English-language studies presenting original research ( in vitro, in vivo, pharmacokinetic,

APA, Harvard, Vancouver, ISO, and other styles

4

McPherson, Christopher. "Premedication for Endotracheal Intubation in the Neonate." Neonatal Network 37, no. 4 (2018): 238–47. http://dx.doi.org/10.1891/0730-0832.37.4.238.

Full text

Abstract:

Endotracheal intubation, a common procedure in neonatal intensive care, results in distress and disturbs physiologic homeostasis in the newborn. Analgesics, sedatives, vagolytics, and/or muscle relaxants have the potential to blunt these adverse effects, reduce the duration of the procedure, and minimize the number of attempts necessary to intubate the neonate. The medical care team must understand efficacy, safety, and pharmacokinetic data for individual medications to select the optimal cocktail for each clinical situation. Although many units utilize morphine for analgesia, remifentanil has

APA, Harvard, Vancouver, ISO, and other styles

5

Nutt, D. "Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70250-0.

Full text

Abstract:

Receptor-binding profiles of antipsychotics differ, with important implications for treatment efficacy and tolerability. Receptors implicated in clinical response and adverse effects include dopamine D2, serotonin 5HT1A and 5HT2A, as well as H1 histamine, M1 muscarinic and alpha1 adrenergic receptors. Varying receptor affinities can explain the clinical profile specific to each compound, including adverse events such as weight gain, metabolic disturbance, hypotension, hyperprolactinaemia and extrapyramidal symptoms.Receptor profiles also play a role when switching between antipsychotics. Consi

APA, Harvard, Vancouver, ISO, and other styles

6

Papandreou, Christos N., Danai D. Daliani, Darrell Nix, et al. "Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer." Journal of Clinical Oncology 22, no. 11 (2004): 2108–21. http://dx.doi.org/10.1200/jco.2004.02.106.

Full text

Abstract:

PurposeTo determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa).Patients and MethodsFifty-three patients (48 with AIPCa) received 128 cy

APA, Harvard, Vancouver, ISO, and other styles

7

Demczar, Dorothy, and Gary M. Levin. "Use of Atypical Antipsychotics on an As-Needed Basis." Journal of Pharmacy Technology 12, no. 4 (1996): 145–48. http://dx.doi.org/10.1177/875512259601200407.

Full text

Abstract:

Objective: To review the literature and determine whether atypical antipsychotics should be used on an as-needed (prn) basis. Data Sources: Pertinent English-language literature dealing with atypical antipsychotics, typical antipsychotics, phamacokinetics, and prn dosing strategies was retrieved from a MEDLINE search (1960–1995). Data Extraction: Articles that discussed either pharmacokinetic parameters or the rationale for using antipsychotics on a prn basis. Data Synthesis: Administration of typical antipsychotics on a prn basis, either alone or in combination with scheduled antipsychotics,

APA, Harvard, Vancouver, ISO, and other styles

8

Markowitz, John S., Barbara G. Wells, and William H. Carson. "Interactions Between Antipsychotic and Antihypertensive Drugs." Annals of Pharmacotherapy 29, no. 6 (1995): 603–9. http://dx.doi.org/10.1177/106002809502900610.

Full text

Abstract:

Objective: To provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensives and to provide recommendations for the selection of antihypertensives in patients receiving antipsychotic therapy. Data Sources: A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports. Study Selection: All available sources were reviewed. Data Extraction: Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinen

APA, Harvard, Vancouver, ISO, and other styles

9

Lee, Jeeyun, Young Suk Park, James Burke, et al. "Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 3608. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3608.

Full text

Abstract:

3608^ Background: Pexa-Vec is an EGFR-targeted vaccinia virus engineered to express granulocyte-macrophage colony stimulating factor (GM-CSF), thereby stimulating direct oncolysis, tumor vascular disruption and anti-tumor immunity (Nat Rev Cancer 2009). Dose-dependent IV Pexa-Vec delivery was defined previously (Nature2011). This study was designed to assess the safety, maximal tolerated dose and anti-tumor activity of Pexa-Vec administered IV in patients with mCRC after failure of standard therapies. Methods: Nine patients were treated at 1 of 3 dose levels (106, 107 or 3x107pfu/kg IV every 2

APA, Harvard, Vancouver, ISO, and other styles

10

Ahmad, Razi, Anwar Habib, and Sana Rehman. "Efficacy of various antihypertensive drugs in the treatment of hypertension in the patients of end-stage renal disease leading to hemodialysis: a retrospective study." International Journal of Advances in Medicine 4, no. 1 (2017): 203. http://dx.doi.org/10.18203/2349-3933.ijam20170112.

Full text

Abstract:

Background: Cardiovascular complications are the leading cause of morbidity and mortality in the patients of end-stage renal disease leading to hemodialysis. Majority of these patients suffers from hypertension and adequate control of blood pressure is a challenge in these patients because of multifactorial etiology and complicated pharmacokinetic changes in these patients. The present study aims is to find out the best possible drug or combination of drugs that can provide better control of blood pressure and improve the quality of life of these patients.Methods: A retrospective study was car

APA, Harvard, Vancouver, ISO, and other styles

11

Suprobo, Gembong Pandhu, Karmini Yupono, and Rudy Vitraludyono. "The Use of Dexmedetomidine on Pediatrics Undergoing MRI Examinations." Journal of Anaesthesia and Pain 2, no. 2 (2021): 76–81. http://dx.doi.org/10.21776/ub.jap.2021.002.02.05.

Full text

Abstract:

Dexmedetomidine, an α2 adrenergic agonist, has been commonly used as an off-label anesthetic adjuvant in various procedures and age groups. Lately, dexmedetomidine is increasingly preferred as sedation for pediatric patients undergoing MRI, which requires the patient to remain still in a deep sedation without disturbing airway patency. Dexmedetomidine administration via intranasal or buccal route is preferred for pediatric patients. Dexmedetomidine does not undergo significant pharmacokinetic changes when used in conjunction with other anesthetics, and has a good safety profile. It is 8-10 tim

APA, Harvard, Vancouver, ISO, and other styles

12

Tan, Antoinette R., Donna Headlee, Richard Messmann, et al. "Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms." Journal of Clinical Oncology 20, no. 19 (2002): 4074–82. http://dx.doi.org/10.1200/jco.2002.01.043.

Full text

Abstract:

PURPOSE: To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every 3 weeks. PATIENTS AND METHODS: Fifty-five patients with advanced neoplasms were treated with flavopiridol at doses of 12, 17, 24, 30, 37.5, and 52.5 mg/m2/d for 5 days; doses of 50 and 62.5 mg/m2/d for 3 days; and doses of 62.5 and 78 mg/m2/d for 1 day. Plasma sampling was performed to characterize the pharmacokinetics of flavopiridol with these schedules. RESULTS: Dose-limiting neutropenia develope

APA, Harvard, Vancouver, ISO, and other styles

13

Sun, Yue, George Binh Lenon, and Angela Wei Hong Yang. "Phellodendri Cortex: A Phytochemical, Pharmacological, and Pharmacokinetic Review." Evidence-Based Complementary and Alternative Medicine 2019 (April 1, 2019): 1–45. http://dx.doi.org/10.1155/2019/7621929.

Full text

Abstract:

Background. Phellodendri Cortex (PC) or Huang Bai. According to the scientific database of China Plant Species and Chinese pharmacopeia 2015 edition, PC has two main species which are Phellodendron amurense Rupr (PAR) or “Guan Huang bai” in Chinese and Phellodendron chinense Schneid (PCS) or “Chuan Huang bai” in Chinese. The crude drugs of PAR and PCS are also called Phellodendri amurensis cortex (PAC) and Phellodendri chinense cortex (PCC), respectively. The medicinal part of the plant is the dried trunk bark. PC has comprehensive therapeutic effects which include anti-inflammatory, antimicro

APA, Harvard, Vancouver, ISO, and other styles

14

Ernst, Michael E., and Lucinda M. Buys. "Reevaluating the Safety of Concurrent Warfarin and Ibuprofen Therapy: A Case Report." Journal of Pharmacy Technology 13, no. 6 (1997): 244–47. http://dx.doi.org/10.1177/875512259701300610.

Full text

Abstract:

Objective: To describe a case of subclinical bleeding and elevated international normalized ratio (INR) associated with the concomitant use of ibuprofen and warfarin. Case Summary: A 74-year-old white woman receiving warfarin for a history of cerebrovascular accident and deep-vein thrombosis with concomitant chronic obstructive pulmonary disease, hypertension, congestive heart failure, coronary artery disease, osteoarthritis, and erosive esophagitis developed significant elevation of the INR after the addition of ibuprofen to her medication regimen. The patient experienced a decrease in hemogl

APA, Harvard, Vancouver, ISO, and other styles

15

Bennett, Charles L., Sony Jacob, Peter Georgantopoulos, Judy Nichols, and Iain C. Macdougall. "Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents." Blood 124, no. 21 (2014): 3516. http://dx.doi.org/10.1182/blood.v124.21.3516.3516.

Full text

Abstract:

Abstract Background: Thirty eight anaphylaxis cases were reported to the FDA during the first year of peginesatide marketing in 2012. Marketing was discontinued as a result. We compare 28 reports from a pilot peginesatide introduction conducted by the largest dialysis organization (LDO) in North America versus the 10 reports of anaphylaxis from usual care settings. The pilot introduction was conducted at 10 LDO centers, a nurse was assigned to each center, and staff were educated on peginesatide dosing, safety, pharmacokinetics, and handling. Methods: Reports in the FDA of anaphylaxis occurrin

APA, Harvard, Vancouver, ISO, and other styles

16

Karapanagiotou, E., H. S. Pandha, G. Hall, et al. "Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers." Journal of Clinical Oncology 27, no. 15_suppl (2009): e14519-e14519. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14519.

Full text

Abstract:

e14519 Background: Reolysin, a wild type reovirus (Dearing strain), replicates preferentially in Ras-activated cancer cells. Preclinical data have demonstrated synergistic tumor kill when reolysin is combined with standard chemotherapies including platinum agents and taxanes, justifying the clinical evaluation of this drug combination. Methods: Pts were initially treated in an open-label, dose-escalating, phase I trial and received iv reolysin, d1–5, iv carboplatin (AUC5), d1, and paclitaxel (175mg/m2), d1, qw3. Reolysin was administered at a starting dose of 3x109 TCID50 and then increased to

APA, Harvard, Vancouver, ISO, and other styles

17

Kasner, Margaret T., Ellen K. Ritchie, David Cutler, et al. "A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy." Journal of Clinical Oncology 35, no. 15_suppl (2017): 7043. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7043.

Full text

Abstract:

7043 Background: Treatment of elderly AML patients is complicated by poor tolerance to standard therapies and multi-drug resistance. It is imperative to explore novel agents which are tolerable and target alternative pathways. KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymerase. We conducted a phase I open-label safety and activity study in elderly subjects with AML who were refractory to or declined standard induction chemotherapy. Five dose levels were tested from 40 to 160 mg daily. Methods: 24 subjects were recruited from 3 institutions with an average age

APA, Harvard, Vancouver, ISO, and other styles

18

Cohen, S. J., M. Zalupski, M. Modiano, et al. "Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma." Journal of Clinical Oncology 25, no. 18_suppl (2007): 15058. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15058.

Full text

Abstract:

15058 Background: Imexon for inj. (Amplimexon®, AMP) is an aziridine-containing iminopyrrolidone which causes G2 arrest, accumulation of reactive oxygen species, and induction of apoptosis in pancreatic cancer cells. AMP demonstrated synergy with gemcitabine (GEM) in preclinical pancreatic cancer models. This phase I study of AMP plus GEM was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT). Secondary endpoints were pharmacokinetics for both agents (PK) and tumor response. Methods: Patients (pts) with previously untreated advanced pancreatic adenocarc

APA, Harvard, Vancouver, ISO, and other styles

19

DiNardo, Courtney D., Joseph Rosenthal, Michael Andreeff, et al. "Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results." Blood 128, no. 22 (2016): 593. http://dx.doi.org/10.1182/blood.v128.22.593.593.

Full text

Abstract:

Abstract Background:MDM2, a negative regulator of the tumor suppressor p53, is overexpressed in a number of cancers including hematological malignancies. Disrupting the MDM2-p53 interaction represents an attractive approach to treat cancers expressing wild-type functional p53, and the inhibition of MDM2 and antitumor activity with the small molecule DS3032b has been demonstrated in preclinical studies and in patients with solid tumors. Here, we report the initial results of the Phase I trial aimed at characterizing the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profil

APA, Harvard, Vancouver, ISO, and other styles

20

Fanale, Michelle, William I. Bensinger, John C. Byrd, et al. "Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,." Blood 118, no. 21 (2011): 3702. http://dx.doi.org/10.1182/blood.v118.21.3702.3702.

Full text

Abstract:

Abstract Abstract 3702 Introduction. Patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) together accounted for 7% of new cancers and 6% of cancer deaths in 2010. Despite therapeutic advances, many of these patients develop relapsed or refractory disease and have poor survival thereafter. CLL, MM, NHL, and HL highly express the CD40 receptor, which is activated by the CD40 ligand (CD40L, CD154) and stimulates downstream proliferation and survival. Lucatumumab is a fully antagonistic human anti-CD40 monoclonal antibody t

APA, Harvard, Vancouver, ISO, and other styles

21

Vogl, Dan T., Noopur Raje, Parameswaran Hari, et al. "Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)." Blood 124, no. 21 (2014): 4764. http://dx.doi.org/10.1182/blood.v124.21.4764.4764.

Full text

Abstract:

Abstract Background Ricolinostat is the first selective oral HDAC6 inhibitor studied clinically in the treatment of MM. Preclinical and phase 1a clinical data support the hypothesis that the safety profile of a selective HDAC inhibitor will facilitate combination therapy with other active agents. No dose limiting toxicities (DLT) were noted in 15 patients (pts) in a phase 1a dose escalation study of ricolinostat at doses up to 360 mg/day where the best response was stable disease (SD). (Raje Blood 2012;120:4061). HDAC6 inhibition impairs the aggresome/autophagy pathway, an alternate pathway to

APA, Harvard, Vancouver, ISO, and other styles

22

Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al. "Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study." Blood 132, Supplement 1 (2018): 399. http://dx.doi.org/10.1182/blood-2018-99-118344.

Full text

Abstract:

Abstract Introduction: Mosunetuzumab is a full-length bispecific CD20/CD3 antibody that redirects endogenous T-cells to kill malignant B-cells by concomitantly binding to CD3 on T-cells and CD20 on B-cells. We report results of an ongoing multicenter Phase 1/1b study (NCT02500407) evaluating mosunetuzumab in relapsed/refractory (R/R) B-cell NHL patients (pts). Methods: Pts received mosunetuzumab intravenously (IV) as follows: Group A, mosunetuzumab administered on day (D) 1 of each 21-day cycle (C); and Group B, ascending doses of mosunetuzumab administered on D1, D8, and D15 of C1, then at a

APA, Harvard, Vancouver, ISO, and other styles

23

Foran, James M., Courtney D. DiNardo, Justin M. Watts, et al. "Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study." Blood 134, Supplement_1 (2019): 4254. http://dx.doi.org/10.1182/blood-2019-123946.

Full text

Abstract:

Background: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in ~3% of individuals with myelodysplastic syndrome (MDS) and have been associated with increased transformation to acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, potent, targeted inhibitor of the mutant isocitrate dehydrogenase 1 enzyme (mIDH1) and is approved in the US for the treatment of newly diagnosed AML with a susceptible IDH1 mutation in patients ≥75 years of age or who have comorbidities that preclude the use of intensive induction chemotherapy, and in adult patients with relapsed or refractory (R/R) AML.

APA, Harvard, Vancouver, ISO, and other styles

24

Lizano-Diez, I., M. Cerezales, and S. Poteet. "The burden of perioperative hypertension/hypotension: a systematic review." European Heart Journal. Acute Cardiovascular Care 10, Supplement_1 (2021). http://dx.doi.org/10.1093/ehjacc/zuab020.164.

Full text

Abstract:

Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Ferrer Background Hypertension/hypotension in the perioperative setting may result in a high economic burden for healthcare systems and patients affected in terms of clinical outcomes. Although previous systematic reviews have shown IV antihypertensive treatments to be highly effective, there is currently a clear gap in the literature regarding a review on the implications of acute hypotensive/hypertensive episodes. Purpose Our goal is to review the outcomes of acute hypertensive/hypotensive epi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!